Citi Pegs FY19 Earnings Growth At 20% With Downside Risks
India Inc. is likely to clock an earnings growth rate of around 20 percent in the current financial year, with a potential for downward revision, according to Citigroup.
Corporate earnings have been muted over the last four years. “We have considered it and so our estimates are below consensus,” Surendra Goyal, head of India equity research at Citigroup, told BloombergQuint, adding that the current 23 percent consensus estimate looks a bit too optimistic.
Citi’s expectation of fourth-quarter earnings is also not that great either. The firm expects a 10 percent growth in earnings for the three-month period, compared to a robust 20 percent plus year-ago. "But the numbers are not weak as they are coming off a decent base," Goyal added.
Also Read: Temper Those Q4 And FY19 Earnings Forecasts
The Sectors Expected To Do Well In Q4
- Domestic automakers
- Metals and mining
Domestic autos, except JLR, saw decent growth in sales. The rural sentiment is picking up. This should help earnings.Surendra Goyal- Head of India equity research, Citigroup
The Sectors That May Lag
Sector-wise Performance Outlook
We expect L&T Infotech and Mindtree from the mid-caps to report decent growth this quarter as well.Surendra Goyal- Head of India equity research, Citigroup
- Expect higher credit costs due to the Reserve Bank of India’s new stressed asset framework.
- Expect private banks/non-banking financial companies to continue to deliver healthy loan growth.
If you look at corporate banks or NBFCs, that growth is very much on track.Manish Shukla, Vice President- Citi India
- Expect a sharp surge in earnings before interest, tax, depreciation, amortisation per tonne for steel.
- Earnings before interest, tax, depreciation and amortisation improvement for aluminum companies could be hurt by cost inflation.
- Expect strong Ebitda improvement in Coal India Ltd. on high e-auction prices and fuel supply agreement price hike.
Tamiflu could be one of the big growth drivers for Cadila. There was a shortage of the drug in the U.S. Cadila would have benefitted from it and that will have a disproportionate impact on numbers this quarter.Prashant Nair- Deputy Head- Research, Citi India
- Topline expected to decline for the seventh straight quarter.
- Commentary from managements on pricing trends and average revenue per user would be key to watch.
Disclaimer: The commentary on BloombergQuint represents the view of external experts. Investors are advised to consult a certified financial advisor/planner when making any investments. No views shared on a BloombergQuint program or story or conversation should be construed as personal advice.
Quintillion Business Media Pvt. (BloombergQuint) is not responsible for any risk or loss that might occur as a result of using this information in any way, regardless of your interpretation of the advice.
BloombergQuint’s digital and social media platforms provide views of only SEBI registered investment advisors/analysts.